Chimerix INC 8-K filings

Chimerix, Inc. has been acquired by Jazz Pharmaceuticals following the completion of a tender offer and subsequent merger on April 21, 2025.

Chimerix announces its Q4 and full-year 2024 financial results, highlighting the FDA acceptance of the dordaviprone NDA and the pending acquisition by Jazz Pharmaceuticals expected to close in the second quarter of 2025.

Chimerix, Inc. is being acquired by Jazz Pharmaceuticals Public Limited Company for $8.55 per share, aiming to enhance Jazz's oncology portfolio with Chimerix's dordaviprone.

Jazz Pharmaceuticals will acquire Chimerix for $8.55 per share in cash, a deal valued at approximately $935 million, to expand its oncology portfolio with dordaviprone, a treatment for rare brain tumors.

Chimerix, Inc. will pause enrollment in the U.S. portion of its Phase 3 ACTION study for dordaviprone due to the ongoing FDA review of its New Drug Application (NDA).

Chimerix, Inc. has entered into a $30 million loan agreement, regained compliance with Nasdaq listing rules, and submitted a new drug application to the FDA.

Chimerix is set to submit a New Drug Application (NDA) for dordaviprone (ONC201) by the end of 2024, seeking accelerated approval for recurrent H3 K27M-mutant diffuse glioma, with a potential PDUFA action date in Q3 2025.

Chimerix, Inc. has amended and restated its Officer Severance Benefit Plan, extending the term to three years with automatic one-year renewals, impacting executive compensation and benefits upon termination.

Chimerix announced its third quarter 2024 financial results, provided an operational update on its clinical programs, and highlighted the promotion of a new Chief Scientific Officer.

Chimerix reported its second quarter 2024 financial results, highlighted progress in its Phase 3 ACTION study for dordaviprone, and provided updates on its ONC206 program.

Chimerix, Inc. has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, as its stock price has remained below $1.00 for 30 consecutive business days.

Chimerix held its 2024 Annual Meeting of Stockholders, electing three Class II directors, approving the 2024 Equity Incentive Plan, and ratifying the selection of Ernst & Young LLP as its independent auditor.

Chimerix announced its first quarter 2024 financial results and provided an update on the progress of its clinical programs, including the ACTION study for dordaviprone (ONC201) and the ongoing dose escalation trials for ONC206.

Chimerix has appointed Marc Kozin to its Board of Directors, while Patrick Machado will retire at the company's 2024 Annual Meeting of Stockholders.

Chimerix announced its fourth quarter and full-year 2023 financial results, highlighted by $204 million in cash and progress in its ONC201 and ONC206 clinical programs.